Skip to main content
Premium Trial:

Request an Annual Quote

John Oyler, BTX

Premium

People in the News

John Oyler has left RNAi startup Galenea as CEO, RNAi News has learned.

According to Pamela Esposito, who is in charge of business development and strategic planning at the company, Oyler left about a month ago to pursue another entrepreneurial opportunity.

She said that the company is "grateful to John for the two years he gave to Galenea."

She noted that Galenea is actively searching for a new CEO.

 

Products & Services

BTX has introduced the BTX high-throughput electroporation system for delivering siRNA and DNA expression vectors into mammalian cells.

According to the company, the system consists of a 96-well electroporation plate along with a 96-well plate handler. The system's interface allows for variable voltage and pulse length, and processes 96 samples in less than 1 minute, the company added.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.